GRN1005 recruiting patients

That's great news, on schedule.
 From Geron Website-
Our clinical development plan for GRN1005 includes a Phase 2 clinical trial in patients with brain metastases arising from NSCLC and breast cancer. If the data from the previously completed Phase 1 trial in metastatic brain cancer are confirmed, and depending upon the strength of the data, the product candidate may have an opportunity for early marketing approval.
We have also entered into a research and collaboration agreement with Angiochem to utilize these receptor-targeting peptides to transport telomerase inhibitors into the CNS.

Good luck in this rigged casino,

Insider buying a good sign

 

  There’s an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 22, Geron Corp.’s Director, Thomas Kiley, invested $100,269.00 into 64,275 shares of GERN, for a cost per share of $1.56. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.

Good luck in this rigged casino,

 

 

Geron needs a partner

The high and low for the week was on the same day Nov. 21st, Monday, $1.80 and $1.41. The $1.41 was a new 52 week low.  Volume was over 3 million for Monday but went back down to normal the next few days.

TJ descided to become active, to raise awareness and funding for spinal cord injury research in America.
Check out Tory's Head in the Clouds blog.

Let me bounce this idea off you folks. Ask Geron how much money in the bank it would take start and finish the Phase I trial. Then have people like TJ, Roman Reed and few famous people, raise the money, put it in a trust account. When the goal is reach the trial can begin. You could have a teletheon and  raise the money quickly.

I'm going to email Geron and see what they say about my idea.

Good luck in this rigged casino,

TJ has descided to become active

TJ descided the become active to raise awareness and funding for spinal cord injury research in America.
Check out Tory's Head in the Clouds blog.

Let me bounce this idea off you folks. Ask Geron how much money in the bank it would take start and finish the Phase I trial. Then have people like TJ, Roman Reed and few famous people, raise the money, put it in a trust account. When the goal is reach the trial can begin. You could have a teletheon and  raise the money quickly

Good luck in this rigged casino,

Kiley Thomas doubled down

Kiley Thomas Director at Geron bought 64,275 more shares at $1.56 on 11-22-2011, for a total of 300,000+.  He believes or more likely he knows the share price will increase soon, because "Chip" the new CEO is wheeling and dealing.
Any price increase will sell a few shares and sell a few covered calls.

Good luck in this rigged casino,

Alex Barkas died suddenly Monday he was on Geron board of directors

Alex Barkas, biotech venture capitalist with Prospect Venture Partners died suddenly on Monday at 64. The cause of death hasn't been determined. He served on the board of Geron.

Geron not adding to Mondays gains, volume flat, share price down 12 cents. No good news yet.


Good luck in this rigged casino,

Nice move up with volume Geron

Closed up 12% with volume over 3.5 million shares. Great. Lets see what happens Tuesday. If we get more volume with a move up then I think we will have good news very soon.

Good luck in this rigged casino,

GERON the future in bio-tech: CIRM President helping Geron sell stem cell busine...

GERON the future in bio-tech: CIRM President helping Geron sell stem cell busine...: The $3 billion California stem cell agency CIRM, its President Alan Trounson say it is in talks with at least three firms in an effert to sa...

CIRM President helping Geron sell stem cell business

The $3 billion California stem cell agency CIRM, its President Alan Trounson say it is in talks with at least three firms in an effert to salvage Geron's orphan stem cell business. This is great news, it needs to be done very soon, 2 or 3 months tops.

Rumor on Yahoo Message Board is 2nd patient has more than a toe wiggle.
Note Geron's share price is up and climbing on a down big day. Volume is up. I brought 500 shares before I new all this at $1.43. It was interesting because my order was for 1000 shares only 500 filled. I think something is in the works by the price rise on a very very bad day and the volume incease.

Good luck in this rigged casino,

Geron 5th Patient injected

The Stanford University School of Medicine and Santa Clara Valley Medical treated the fifth patient in the Geron Corp. sponsored trial of a human embryonic-stem-cell-derived treatment for spinal cord injury on Nov. 16th.
Humans may need longer than a year to show results. It was shown that primates require more time than rats to recuperate.
Phase I results for GRN1005, Geron found the peptide/paclitaxel conjugate to be generally well tolerated. Since paclitaxel itself is an approved product, this is good news. Geron plans to initate two Phase II clinical trials for GRN1005 soon [December 2011] with data to become available in the first half of 2013. With good results it will most likely be fast tracked.


ACTC is in two Phase 1/2 trials, which injects embryonic stem cells into the eye,  one for Stargardt's Macular Dystrophy and Dry Age Related Macular Degeneration. Interesting news, patients want their second eye injected. That's a very strong indication that they are experiencing improvement. The studies are notable because Catholic nuns are among the patients. That is wild.

I'm long Geron and ACTC.

Good luck is this rigged casino,

Ruff Week for Longs

The high for the week was $2.32 on Nov. 14th the new low for the year was $1.50 on Nov. 18th.  The five day avg, volume was 3,607,10 shares, ten day avg. was 2,314,856, three month avg. volume was 1,597,230.  We will go lower without positive news. Geron decision to continue pursuing the oncology programs will make or break them. By the end of 2012 if the four Phase II trial results are less then outstanding, I will sell most of my shares. Right now any move over $2.00 will sell a few shares and covered calls.

Partners are still needed.

Good luck in this rigged casino,

Setback for the whole stem cell research industry

Joseph Pantginis an analyst with Roth Capital Partners said it would have taken five to ten years before Geron's lead stem cell product reached the market.

This was a classic business calculation, you have two blockbuster programs but only enough money for one, so you choose the one that is further along.

Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.

The share price is worrying me. It could go below a dollar. Only good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding I will sell most of my shares. For now any move over $2 I will sell some shares and sell a few covered calls.

I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company.

Good luck in this rigged casino,

Geron now totally focused on Imetelstat

Imetelstat could be part initial therapy and maintence thrapy in 90% of all cancers.  Whether as a single agent or in combination with other drugs, it looks like a telomerase inhibitor can have a role in cancer treatment. The Phase II trial will answer that question at the end of 2012. If so, Imetelstat may be the first and only drug that has the benefit that hits CSCs. It could be the blockbuster of all time in cancer. That's why GERN decided it could not afford to expend its limited resources on ESCs. It's still very dispointing but with limited funds a choice had to be made.

Good luck in this rigged casino,

Chip buys 80,000 shares Geron

That's  the rumor on Yahoo's Message Broad. Chip will do what it takes to made this company survive. Over 9 million shares traded down 20%. I bought at $1.85 and $1.80 pre-market, that was a mistake. I think we'll go back to $2+ after the new year starts.

Again, I'm very disappointed by the halting of the stem cell research. It's very sad.

Geron plans to partner all stem cell program. They will be lucky to get pennies on the dollar.

Good luck in this rigged casino,

Geron halting stem cell research

Geron to focus on its novel cancer programs.

This is bad short term, good long term. Geron saw the writing on the wall, running out of money fast. They now may have time to get a blockbuster product to market before they have to do a 2nd offering at under $2.00.

Geron plans to partner all stem cell programs, meaning the partner will have to foot the total bill.

The GRN1005  is entering two Phase 2 trials this year data from these trials should be out before the end of the 2nd quarter of 2013.

The four Phase 2 clinical oncology studies will have data by the end of 2012. If any are good Geron will find a partner.

Conference call Nov. 15 at 9AM I will be listening.

I am very disappointed by the halting of the stem cell research. I still believe in the science. Geron needs a very very rich partner to fund this.

We will take a big hit tomorrow. I will buy a few shares around $1.75 or lower.

Good luck in this rigged casino,

Unlocking Amazing Potential of Stem Cell Therapy

NEW YORK, NY, Nov 14, 2011 (MARKETWIRE via COMTEX) -- The case for increased stem cell funding is growing by the day as the potentially lifesaving effects of regenerative medicine continue to be revealed. Scientists argue that stem cells are the future of healthcare, and that regenerative medicine is one of the most misunderstood fields in biotechnology. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Advanced Cell Technology, Inc. (ACTC, Trade ) and Geron Corporation (GERN, Trade ). Ground breaking studies out of Japan earlier this month showed the vast reach of stem cell medicine. A research team at Japan's RIKEN Center for Developmental Biology successfully used stem cells to synthesize a fully functioning organ entirely from scratch. The team somehow managed to take mouse stem cells and transformed them into a working pituitary gland, which is a small organ that lives at the base of your brain and produces hormones that help you grow.
The Bedford Report releases stock research on the Biotechnology Insurance Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Headlines regarding the funding (or lack thereof) for embryonic stem cell research have a habit of moving all stem cell related stocks, even those not involved in the controversial sector. Very few publicly traded companies are actually engaged in embryonic stem cell research.
Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The company recently reported a loss from operations of $6.9 million for the third quarter ended September 30, 2011. This compares with a loss from operations of $5.4 million reported in the third quarter of 2010.
Geron Corporation is developing cell therapies from differentiated human embryonic stem cellswith the first product in a Phase 1 clinical trial for spinal cord injury. For the third quarter of 2011, the company reported a net loss of $19.5 million, or $0.16 per share, compared to $18.3 million, or $0.19 per share, for the comparable 2010 period
Let's see if this will move the share price. I'm long big time GERN and ACTC.

Good luck in this rigged casino,

Geron week in review

No great news from Geron, but there was alot of good news stories on stem cells. I believe in the science more each day. Can Geron come up with a FDA approved blockbuster before they run out of money. It will be very very close. GRN1005 is there best shot. If the data from the previously completed Phase 1 trail in metastatic brain cancer are confirmed and depending upon the strength of the data the product candidate may have an opportunity for early marketing approval. I will feel better about Geron's viability if and when they find a partner with deep pockets.
The high for the week was $2.43 on Nov. 8  and the low was $2.21 on Nov. 10. The volume is very low. Five day avg. volume is 922,200 shares, ten day avg. volume 1,069,566 shares and the three month avg  1,446,080 shares.
I didn't get any $3 calls my bid was to low.

Good luck in this rigged casino,

Treating Parkinson's with stem cells

Major step in treating Parkinso's with stem cell transformation. Previous difficulties in transforming stem cells into neurons, which are killed off when Parkinson's disease strike. have now beed resolved. Testing on monkeys has shown the cells not only survived and function normally but begin to reverse the process of poor movement problems. Now the prospect of transplanting freshly grown dopamine producing cells into human patients to treat the disease has been significantly raised.
Stem cell therapy may still be some way off. However, this study has shown for the first time that it is possible to transplant nerve cells that work from human stem cells.

Above is part of a story from Digital Journal Nov 7, 2011 by Kev Hedges.

Looks like the market will be down big. Buy a few shares from your wish list. If Geron goes under $2.20 will buy a few $3.00 calls. Not sure what month.

Good luck in this rigged casino,

Geron silent for?

Geron also my be silent because of something happening with the FDA and must be close to some conclusion, and are in a very sensitive time about any leaked infor.

GRN1005 Phase 1 final results Nov. 14th. If the data from the previously completed Phase 1 trail in metastatic brain cancer are confirmed and depending upon the strength of the data, the product candidate may have an opportunity for early marketing approval.

Something good is in the works. May buy some $3 calls.

Good luck in this rigged casino,

Geron week in Review

Geron's high for the week was $2.51 on Monday Oct. 31st. The low for the week was $2.21 on Tuesday Nov. 1st. The avg. volume has been going down only 1,189,440 shares for 5 day avg, 3 month is 1,601,150.
Hoping "Chip" the new CEO will work his magic. Thinking of putting a small bet on Chip's ability. May buy a few Jan 12 $3.00 calls. But after losing $600  the last time I bet on good news coming, I'm a little gun shy.

Good luck in this rigged casino,

Patent case against Viacyte

After thinking about the conference call today, the strategic review at the end of this year should move the stock price higher. It was interesting that they keep on saying there would be no comments on forward movement. Why say this? Chip must be working on a deal or deals that will reduce the cash burn with big pharma and not want anyone to say anything to mess it up.
Good news I think in the patent case against on Viacyte. In the latest filing in the case the last paragraph. The parties have been negotiating a settlement. This could be big.

Good luck is this rigged casino,

End of the Year will talk strategist moves

Listened to call today at 9AM. Nothing that will move share price. All Phase II trial are going well. Cash burn rate for this year will be $65 million. They have $185 million in cash. Strategist talk at the end of this year should be move share price, hopefully up.

Good luck in this rigged casino,

Geron beat by 2 cents

It's not as good as it sounds. Geron lost 16 cent a share in the 3Q, the estimate was for a 18 cents a share lost.  The revenes fell 60% year/year to 0.22 min vs the 0.97 min consensus. I don't understand why this is going down. With the GE and Corning deal I would think revenes would be going up.
I hope "Chip" has some good news Friday at AM.

Good luck in this rigged casino,

Geron Q3 Results Nov 4 at 9AM

Quarterly Financial Conference Calls

November 4, 2011, 6:00am PDT / 9:00am EDT

Q3 2011 Financial Results Conference Call, Menlo Park, CA
Please use the following URL to access the webcast: http://www.media-server.com/m/p/2j4c3p37

Look for increase in Revenue Growth it was down 53.80% . Revenue should start climbing with all there deals with GE, Corning ect. Buy on the dips and start the rips up.

Good luck in this rigged casino,